Analysts have been eager to weigh in on the Healthcare sector with new ratings on Atricure (ATRC – Research Report), SAGE Therapeutics (SAGE – Research Report) and Repligen (R ...

SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.

Sage Therapeutics Inc (SAGE) reports significant growth in ZURZUVAE prescriptions and collaboration revenue, alongside a ...

Sage Therapeutics reported strong Q1 2025 growth, with ZURZUVAE leading the charge in postpartum depression treatment.

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.80 per share a year ago. These ...

A total of 4 analyst ratings have been received for Sage Therapeutics, with the consensus rating being Neutral. The average one-year price target stands at $9.5, suggesting a potential 21.95% upside.

We're tailored to athletes, kids and families. We're a day park... Daily riding. You show up, pay your ticket price and you ...

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ...

Palmdale School District’s SAGE Planetarium has a new concrete plaza called the SAGE Space and Aeronautics Promise Plaza, where SAGE Magnet Academy students can sit on the concrete ...

That's not all the new Legend of Zelda amiibo you can expect in the future, as an additional fifth toy is currently in ...

Biogen BIIB will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's ...

Riju, the Gerudo chief and Sage of Lightning, is a powerful ally in Tears of the Kingdom. Her amiibo will allow players to access exclusive in-game items and bonuses. Currently, pre-orders for Riju's ...